Merck reports positive results from trial of pneumonia vaccine
German pharmaceutical company Merck KGaA (Merck) has announced positive data from the Phase III STRIDE-10 trial of its investigational pneumococcal conjugate vaccine, V116. The 21-valent V116 vaccine is in Phase III development to prevent invasive …